Meiji and Cerexa drop carbapenem on safety data
This article was originally published in Scrip
Executive Summary
Japan's Meiji Seikaand its development partner Cerexa have halted the development of the carbapenem antibiotic ME1036 following a review of safety data from a US Phase I clinical trial.